A computational approach based on the colored Petri net formalism for studying multiple sclerosis.
Colored petri nets
Computational models
Multiple sclerosis
Sensitivity analysis
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
10 Dec 2019
10 Dec 2019
Historique:
received:
24
10
2019
accepted:
05
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
11
2
2020
Statut:
epublish
Résumé
Multiple Sclerosis (MS) is an immune-mediated inflammatory disease of the Central Nervous System (CNS) which damages the myelin sheath enveloping nerve cells thus causing severe physical disability in patients. Relapsing Remitting Multiple Sclerosis (RRMS) is one of the most common form of MS in adults and is characterized by a series of neurologic symptoms, followed by periods of remission. Recently, many treatments were proposed and studied to contrast the RRMS progression. Among these drugs, daclizumab (commercial name Zinbryta), an antibody tailored against the Interleukin-2 receptor of T cells, exhibited promising results, but its efficacy was accompanied by an increased frequency of serious adverse events. Manifested side effects consisted of infections, encephalitis, and liver damages. Therefore daclizumab has been withdrawn from the market worldwide. Another interesting case of RRMS regards its progression in pregnant women where a smaller incidence of relapses until the delivery has been observed. In this paper we propose a new methodology for studying RRMS, which we implemented in GreatSPN, a state-of-the-art open-source suite for modelling and analyzing complex systems through the Petri Net (PN) formalism. This methodology exploits: (a) an extended Colored PN formalism to provide a compact graphical description of the system and to automatically derive a set of ODEs encoding the system dynamics and (b) the Latin Hypercube Sampling with PRCC index to calibrate ODE parameters for reproducing the real behaviours in healthy and MS subjects.To show the effectiveness of such methodology a model of RRMS has been constructed and studied. Two different scenarios of RRMS were thus considered. In the former scenario the effect of the daclizumab administration is investigated, while in the latter one RRMS was studied in pregnant women. We propose a new computational methodology to study RRMS disease. Moreover, we show that model generated and calibrated according to this methodology is able to reproduce the expected behaviours.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple Sclerosis (MS) is an immune-mediated inflammatory disease of the Central Nervous System (CNS) which damages the myelin sheath enveloping nerve cells thus causing severe physical disability in patients. Relapsing Remitting Multiple Sclerosis (RRMS) is one of the most common form of MS in adults and is characterized by a series of neurologic symptoms, followed by periods of remission. Recently, many treatments were proposed and studied to contrast the RRMS progression. Among these drugs, daclizumab (commercial name Zinbryta), an antibody tailored against the Interleukin-2 receptor of T cells, exhibited promising results, but its efficacy was accompanied by an increased frequency of serious adverse events. Manifested side effects consisted of infections, encephalitis, and liver damages. Therefore daclizumab has been withdrawn from the market worldwide. Another interesting case of RRMS regards its progression in pregnant women where a smaller incidence of relapses until the delivery has been observed.
RESULTS
RESULTS
In this paper we propose a new methodology for studying RRMS, which we implemented in GreatSPN, a state-of-the-art open-source suite for modelling and analyzing complex systems through the Petri Net (PN) formalism. This methodology exploits: (a) an extended Colored PN formalism to provide a compact graphical description of the system and to automatically derive a set of ODEs encoding the system dynamics and (b) the Latin Hypercube Sampling with PRCC index to calibrate ODE parameters for reproducing the real behaviours in healthy and MS subjects.To show the effectiveness of such methodology a model of RRMS has been constructed and studied. Two different scenarios of RRMS were thus considered. In the former scenario the effect of the daclizumab administration is investigated, while in the latter one RRMS was studied in pregnant women.
CONCLUSIONS
CONCLUSIONS
We propose a new computational methodology to study RRMS disease. Moreover, we show that model generated and calibrated according to this methodology is able to reproduce the expected behaviours.
Identifiants
pubmed: 31822261
doi: 10.1186/s12859-019-3196-4
pii: 10.1186/s12859-019-3196-4
pmc: PMC6904991
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
623Références
Ther Clin Risk Manag. 2017 Jul 14;13:871-879
pubmed: 28761351
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Lancet Neurol. 2015 Mar;14(3):263-73
pubmed: 25662901
Immunology. 2004 May;112(1):38-43
pubmed: 15096182
BMC Bioinformatics. 2013;14 Suppl 16:S9
pubmed: 24564794
Lancet. 2013 Jun 22;381(9884):2167-75
pubmed: 23562009
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):528-44
pubmed: 22583435
Chem Rev. 2005 Jul;105(7):2811-28
pubmed: 16011325
Lancet Neurol. 2010 Apr;9(4):381-90
pubmed: 20163990
Nat Rev Neurol. 2018 Dec;14(12):723-734
pubmed: 30451970
J Clin Med. 2018 Nov 28;7(12):null
pubmed: 30486504
Semin Neurol. 2018 Apr;38(2):212-225
pubmed: 29791948
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Hosp Pharm. 2016 Dec;51(11):928-939
pubmed: 28057953
Immunol Lett. 2005 Jan 31;96(2):195-201
pubmed: 15585323
J Neurol Sci. 2013 Jan 15;324(1-2):10-6
pubmed: 23154080
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Brain. 2004 Jun;127(Pt 6):1353-60
pubmed: 15130950
Prog Neurobiol. 2011 Jan;93(1):1-12
pubmed: 20946934
Neurology. 2016 Nov 15;87(20):2074-2081
pubmed: 27760868